Phase 3 randomized study to evaluate the safety and efficacy of aprotinin (Trasylol®) administered by inhalation nebulization in patients diagnosed with SARS-CoV-2 (COVID-19) with moderate severity compared to standard therapy. - EFFICACY OF APROTININE IN COVID-19.

开始日期2020-10-16

申办/合作机构-

IRCT20200705048023N1

/ Suspended临床3期IIT

Evaluation of therapeutic safety and efficacy of tranexamic acid or aprotinin in absolute blood loss and transfusion in pediatric patients undergoing craniosynostosis surgery

开始日期2020-07-22

申办/合作机构

Tehran University of Medical Sciences

100 项与抑酶肽(Bayer AG) 相关的临床结果

登录后查看更多信息

100 项与抑酶肽(Bayer AG) 相关的转化医学

登录后查看更多信息

100 项与抑酶肽(Bayer AG) 相关的专利（医药）

登录后查看更多信息

5,949

项与抑酶肽(Bayer AG) 相关的文献（医药）

2025-08-01·PEDIATRIC ANESTHESIA

The Effect of Prophylactic Use of Antifibrinolytics During Pediatric Non‐Cardiac Surgeries on Bleeding and Transfusions: A Systematic Review and Meta‐Analysis

Review

作者: Hickey, Katherine Schertz ; Nellis, Marianne E. ; Duron, Vincent ; Demetres, Michelle ; Karam, Oliver ; Smith, Morgan ; Faraoni, David ; Wu, Yeu Sanz

ABSTRACT:

Objectives:

The objective of this meta‐analysis is to determine the effect of intraoperative tranexamic acid, aminocaproic acid, and aprotinin on bleeding in pediatric surgery.

Study Design:

A literature search was performed for the meta‐analysis and systematic review in the following databases from inception until April 2023: Ovid MEDLINE, Ovid EMBASE, and The Cochrane Library. Studies included patients under 18 years of age, non‐cardiac surgery, and administration of antifibrinolytics. Forest plots were used for statistical analysis. Primary outcomes were intraoperative blood loss and intraoperative blood transfusions.

Results:

One hundred thirty articles met inclusion. Tranexamic acid compared to control resulted in an estimated blood loss of −410.0 mL p‐value = < 0.001 for scoliosis surgery, −14.0 mL/kg p‐value = < 0.001 for craniofacial surgery, and −21.0 mL p‐value < 0.001 for tonsillectomy/adenoidectomy surgery. Aminocaproic acid compared to control resulted in an estimated blood loss of −464.0 mL p‐value < 0.001 for scoliosis surgery. Tranexamic acid compared to aminocaproic acid resulted in an estimated blood loss of −391.0 mL p‐value < 0.001 for scoliosis surgery. For blood transfusion during craniosynostosis surgery, tranexamic acid compared to control resulted in a mean decrease of −7 mL/kg p‐value = 0.010 and aprotinin compared to control resulted in a mean decrease of −20.0 mL/kg p‐value < 0.001. The analysis for VRO/VDRO and hip reconstruction did not reach statistical significance.

Conclusions:

In craniofacial, scoliosis, and tonsillectomy/adenoidectomy surgery, prophylactic administration of tranexamic acid results in lower estimated blood loss. Tranexamic acid and aprotinin are effective for reducing transfusion in craniofacial surgery. For scoliosis surgery, tranexamic acid is more efficacious than aminocaproic acid. More literature is needed to assess the efficacy of tranexamic acid in VRDO/VRO and hip reconstruction surgery and the efficacy of different dosing regimens.

2025-06-02·Journal of neurosurgery. Case lessons

Anaphylaxis associated with Tisseel fibrin sealant during re-resection of a craniopharyngioma: illustrative case

Article

作者: Akker, Erica L. T. van den ; Dammers, Ruben ; Djuric, Niek ; Emons, Joyce A. M. ; Schröder, Rosalie D. ; Spoor, Jochem K. H.

BACKGROUND:

Tisseel is a widely used fibrin sealant often used in cranial surgery to control bleeding from the cavernous sinus, often with successful results.

OBSERVATIONS:

The authors present the case of a 10-year-old female patient who developed anaphylaxis during a re-resection of a craniopharyngioma, shortly after the application of Tisseel in the cavernous sinus. This reaction included a strong drop in blood pressure, rise in pulse, increase in oxygen requirements, and diffuse erythema and urticaria soon after after the use of Tisseel. Symptoms normalized after administration of adrenaline, clemastine, and hydrocortisone. A skin prick test later confirmed that the allergic reaction had not been to a single component of Tisseel but to a combination of its components.

LESSONS:

This case and the accompanied literature can aid in recognizing patients at risk for an anaphylactic reaction against aprotinin. It also serves to remind us that medicine used locally in the surgical field can also cause anaphylaxis.https://thejns.org/doi/10.3171/CASE2517

2025-05-20·Cureus Journal of Medical Science

Low Secretory Leukocyte Protease Inhibitor (SLPI)-Level Potentiates Alternaria Extract-Induced T-Helper 2 (Th2) Airway Inflammation via the Interleukin-33 (IL-33) Pathway

Article

作者: Kurosawa, Hajime ; Hirano, Taizo ; Koarai, Akira ; Sugiura, Hisatoshi ; Ohkouchi, Shinya

Introduction Serine proteases play a critical role in the augmented release and cleavage of IL-33, leading to the expansion of group 2 innate lymphoid cells (ILC2s) and T-helper 2 (Th2) airway inflammation. However, the protective regulation of protease-dependent interleukin-33 (IL-33) activation remains poorly understood. Therefore, we investigated the role of secretory leukocyte protease inhibitor (SLPI), as a serine protease inhibitor, in this protective regulation and aimed to clarify its contribution to type 2 immunity. Methods We evaluated the role of SLPI in the Alternaria extract-induced expansion of ILC2s and Th2-type airway inflammation via IL-33, using three models: SLPI-deficient mice, an in vivo SLPI knockdown model with shRNA, and an in vitro model utilizing primary human bronchial epithelial cells (HBECs) exposed to Alternaria extract under various conditions, including plasmid transfection. Results We showed that two mouse models of downregulation of SLPI gene expression augmented Alternaria extract-induced release of IL-33 and the expansion of ILC2s, together with Th2 airway inflammation. Furthermore, two treatment models using SLPI KO mice, administration of a serine protease inhibitor, bovine pancreatic trypsin inhibitor, or anti-IL-33 antibody, attenuated Th2 airway inflammation. In two in vitro experiments, SLPI, as a serine protease inhibitor, prevented both the release of IL-33 from HBECs and the cleavage of full-length IL-33 to shorter mature forms by neutrophil elastase. Discussion These findings suggest that SLPI functions as a key serine protease inhibitor in regulating IL-33-mediated type 2 immune responses. Low SLPI levels may contribute to the pathogenesis of asthma by promoting Th2 inflammation, highlighting SLPI as a potential therapeutic target in patients with low SLPI expression.

项与抑酶肽(Bayer AG) 相关的新闻（医药）

2025-07-10

·EINPresswire

Antifibrinolytic Drugs Market to Hit $19.3 Billion by 2026 Amid Rising Demand for Hemorrhage Control

North America accounted for majority of the market share in 2018 and is anticipated to continue this trend during the forecast period. PORTLAND, OR, UNITED STATES, July 10, 2025 / EINPresswire.com / -- The Antifibrinolytic Drugs Market size was estimated at $13.59 billion in 2018 and is expected to hit at $19.33 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026. The report provides a detailed analysis of the market size & estimations, top investment pockets, top winning strategies, drivers & opportunities, competitive scenario, and wavering market trends. ► Don't Miss Out “Download Your Exclusive Sample PDF Report” Now: https://www.alliedmarketresearch.com/request-sample/6279 Antifibrinolytics are one of the most commonly used drugs to prevent fibrinolysis by blocking the activation of plasminogen proenzyme and plasmin. This intervention is critical to avoid clotting in areas that are prone to fibrinolysis such as the oral cavity, nasal cavity and female genitalia. Recommended antifibrinolytic drugs include Epsilon aminocaproic acid, tranexamic acid, Amicar, aminocaproic acid, aprotinin, and Cyklokapron. Also, these drugs find their application in surgery such as heart surgery, neurosurgeries and dental surgery. In addition, women use antifibrinolytic drugs to control heavy menstruation. Major market players covered in the report, such as - Akorn Inc., Aurobindo Pharma Limited, Bayer AG, Ferring Holding SA, Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vitruvias Therapeutics Inc. Key Benefits for Stakeholders - • The report provides quantitative analysis of market segments, current trends, strategies and potential of antifibrinolytic drugs market research to identify potential antifibrinolytic drugs market opportunities in genetics. • In-depth analysis of this sector helps identify current market opportunities. • Market analysis and information related to key drivers, restraints and opportunities are provided. • Porter's Five Forces Analysis identifies the capabilities of buyers and suppliers to enable stakeholders to make profitable business decisions and strengthen the network of buyers. • The largest countries in each region are listed according to their contribution to the global market. • Focusing on market players makes benchmarking easier and provides a clear understanding of the current market situation. • The report includes regional and global antifibrinolytic drugs market analysis, key players, market segments, application areas and Market growth strategies. ★ Procure Complete Report [ 220 Pages PDF with Insights, Charts, Tables, and Figures ] @ https://www.alliedmarketresearch.com/request-for-customization/6279 Antifibrinolytic drugs or agents are used in specific situations or in combination with clotting factor replacement to treat hemophilia. These prevent the breakdown of blood clots by counteracting chemicals in the mucous membrane. Antifibrinolytics are increasingly being used in operations associated with high risk of bleeding. These drugs are useful in the management of optimal coagulation. TABLE OF CONTENT - CHAPTER 1 - INTRODUCTION: 1.1. Report description 1.2. Key market segments 1.3. List of key players profiled in the report 1.4. Research methodology 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models CHAPTER 2 - EXECUTIVE SUMMARY: 2.1. Key findings of the study 2.2. CXO Perspective CHAPTER 3 - MARKET OVERVIEW: 3.1. Market Definition and Scope 3.2. Key Findings 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. Market Share Analysis/Top Player Positioning 3.4. Porter’s Five Forces Analysis 3.5. Market Dynamics 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities… 3.6. COVID-19 Impact Analysis on the market North America accounted for the largest share of the antifibrinolytic drugs market in 2018 and is expected to continue this trend during the forecast period. This is due to the increasing number of women using these drugs to control heavy periods. Additionally, a significant increase in surgeries in this region is driving the market growth. However, the Asia-Pacific region is expected to experience rapid growth due to the rise in road accidents and the increase in the use of these drugs by women to control menstrual cycle. 👉 For Purchase Inquiry of Report: https://www.alliedmarketresearch.com/purchase-enquiry/6279 The antifibrinolytic drugs market is expected to witness a significant growth in the coming years. This market has gained interest of the healthcare and medical sectors owing to increased prevalence of hypertension throughout the globe. Furthermore, the global antifibrinolytic drugs market is segmented on the basis of product type, end user, and region. leading market players have been introducing various strategies to help enterprises move their on-premise models to on-demand models. Frequently Asked Questions? Q1. What is the total market value of antifibrinolytic drugs market report? Q2. Which are the top companies holding the market share in antifibrinolytic drugs market? Q3. Which are the largest regions for this Market? Q4. What is the leading technology of antifibrinolytic drugs market? Q5. What are the major drivers for this specific Market? Q6. What are the upcoming key trends in the antifibrinolytic drugs market report? About Us - Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Pawan Kumar, the CEO of Allied Market Research is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. David Correa Allied Market Research + +1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-01-20

·药时空

一文拿捏 | 从大肠杆菌包涵体中获取重组人胰岛素的下游纯化工艺

导读近年来全球糖尿病患者数量持续上升，对胰岛素的需求不断增加，而经济实惠的胰岛素供应不足，因此开发高效经济的生产工艺至关重要。重组人胰岛素生产主要有大肠杆菌包涵体和酵母表达系统两种途径，大肠杆菌因生长快、成本低等优势成为主要宿主，但包涵体路线需复杂的下游处理。新加坡研究人员曾在Bioresources and Biprocessing上发表了题目为《Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies》的综述。重点阐述了从大肠杆菌包涵体生产重组胰岛素下游加工的各个环节，并对每个环节的方法、条件和影响因素进行了详细讨论。从大肠杆菌包涵体中纯化重组人胰岛素/类似物的下游工艺很复杂，涉及多个步骤，包括包涵体回收、洗涤、溶解和氧化亚硫酸化、氰化溴裂解、缓冲液交换、色谱纯化、pH沉淀和锌结晶、胰岛素原折叠、酶切和制剂等，且每个步骤中采用的方法对下一步的产品纯度和产量产生重大影响。图1 重组人胰岛素及其类似物下游加工的一般工作流程一、包涵体回收与洗涤由于异源蛋白在大肠杆菌中以不溶性细胞质包涵体形式存在且不分泌到培养基，所以需要特定方法进行回收。破坏细胞包膜的机械方法包括超声处理、在胶体磨中研磨细胞悬浮液或通过Manton-Gaulin高压等方式破碎细胞膜，该方法能有效地破坏细胞，但可能会更严重地损害包涵体中的蛋白质质量[1]。在基于溶菌酶的方法中，添加溶菌酶以消化细胞包膜。溶菌酶可裂解肽聚糖的骨架，使细胞结构被破坏，随后通过膜微滤或离心技术从全细胞裂解物中分离出包涵体。常用的洗涤缓冲液添加剂有尿素、Triton X-100、EDTA、甘油、溶菌酶、NaCl、Tween 20等，其中尿素和Triton X-100最为常见。大肠杆菌细胞壁由磷脂、蛋白质、肽聚糖和脂多糖组成，使用去污剂、低浓度尿素、溶菌酶和EDTA进行选择性萃取有助于去除细菌细胞壁成分。Triton X-100能去除膜磷脂和碎片，促进碎片和可溶性蛋白从包涵体上解离。洗涤优化要确保洗涤缓冲液不会溶解所需的重组蛋白，此外离心次数、速度和洗涤温度等参数也需要优化，以实现时间和成本的有效控制，提高生产效率。图2 蛋白质-添加剂的相互作用模式二、包涵体溶解及氧化亚硫酸化包涵体通常使用高浓度变性剂，如胍盐酸盐和尿素能完全破坏蛋白质结构，对于含多个半胱氨酸残基的蛋白质，可添加二硫苏糖醇（Dithiothreitol ，DTT）或β-巯基乙醇（Mercaptoethanol，BME）防止错误二硫键形成。在正确的构象中，硫解步骤对于保持其展开形式至关重要，防止在溶解过程中和蛋白质复性之前的初始纯化步骤中形成可能不正确的二硫键，此外氧化硫化分解有助于提高后续复性产量。pH值和温度是可能影响反应溶解和硫解速率的因素，为了获得最大产量，监测硫解反应的温度和持续时间以确保反应完成非常重要。三、溴化氰裂解及缓冲液交换在大肠杆菌蛋白质翻译过程中，重组蛋白以融合蛋白形式表达，N端起始氨基酸为N-甲酰甲硫氨酸（N-Formylmethionine，fMet）。fMet会被人体免疫系统识别为异物，可能引发不必要的免疫原性反应，因此在纯化前需将其去除，溴化氰裂解就是用于切断胰岛素原的甲硫氨酸连接子，从而去除fMet这一信号序列。该方法的缺点是切割特异性低，溴化氰蒸发时间长，其高毒性和挥发性以及释放产物可能发生化学修饰。另一种方法是使用蛋白质蛋白酶来切割融合蛋白，但必须确保蛋白酶在正确的位点切割以去除N末端融合肽。缓冲液交换能去除影响蛋白功能和稳定性的试剂，使蛋白适应后续操作，主要通过三种方法实现。透析：利用渗透压使溶质透过半透膜，是传统的脱盐和缓冲液交换方法。适合易沉淀的敏感蛋白，但耗时久且需较大的膜表面积。超滤：借助离心力或其他外部压力使小分子溶质透过多孔膜，而大分子溶质被截留，从而实现脱盐和缓冲液交换，同时能浓缩蛋白样品。在工业生产中，超滤常用于包涵体溶解和亚硫酸化反应后，去除高浓度尿素和亚硫酸化试剂；在蛋白复性后，也能将复性样品浓缩并交换缓冲液，为后续的酶促转化提供合适环境。尺寸排阻色谱：基于分子大小差异进行分离，小分子如盐类可与较大的肽段分离，是透析的快速替代方法，稀释因子低。四、色谱纯化与沉淀 4.1 色谱纯化亲和色谱（Afnity Chromatography，AC）：基于配体与目标蛋白的特异性结合，需在胰岛素原分子上融合合适的标签。融合标签不仅有助于纯化，还能提升胰岛素原稳定性和表达水平，但基因融合在下游处理时，需考虑标签的去除及对后续分析的影响，且AC树脂成本较高。离子交换色谱（Ion‑Exchange Chromatography，IEX）：根据分子电荷差异分离，可选用阴离子交换色谱或阳离子交换色谱，胰岛素及其前体具有可离子化基团，IEX可用于纯化折叠或磺化的胰岛素原。反相色谱（Reversed‑phase Chromatography，RP）：依据分子与固定相的疏水相互作用分离，通常在胰岛素原酶促转化为胰岛素后使用。RP能有效去除胰岛素原未充分裂解或错切产生的杂质，C8柱因胰岛素的分子量和疏水性成为常用选择，常用乙腈作为洗脱剂[2]。疏水相互作用色谱（Hydrophobic Interaction Chromatography，HIC）：与RP类似基于疏水性分离，但HIC吸附剂疏水性较弱，洗脱无需有机溶剂，对敏感蛋白更温和。尺寸排阻色谱（Size Exclusion Chromatography，SEC）：根据分子大小分离，是较温和的技术，常用于胰岛素纯化的抛光步骤，也可在蛋白质折叠液相色谱中与复性过程结合。混合模式色谱（Mixed‑Mode Chromatography，MMC）：利用多种相互作用实现分离，在胰岛素纯化中逐渐受到关注，其混合模式离子交换剂与传统离子交换剂相比具有不同选择性，可在高盐条件下结合蛋白质，减少脱盐或稀释步骤。表1 胰岛素原（PI）纯化中的亲和色谱法 4.2 沉淀方法 pH沉淀：利用蛋白质在等电点时溶解度最低的特性，通过调节溶液pH使胰岛素/胰岛素类似物沉淀，从而与杂质分离，还能浓缩蛋白。例如可将溶解的融合蛋白pH调至5.0使其沉淀，离心后再溶解于碱性缓冲液提高蛋白纯度；在胰岛素原复性后，也可调节pH沉淀杂质，收集含正确折叠胰岛素原的上清。锌结晶：胰岛素在锌离子存在下可形成六聚体等聚集体，利用这一特性在纯化过程中加入锌离子使胰岛素结晶，可用于胰岛素的浓缩和临时保存，减少其在储存过程中的物理和化学降解[3]。五、复性胰岛素由A、B两条多肽链通过二硫键连接而成，胰岛素原在体外复性时，需去除高浓度变性剂，促使二硫键正确形成和蛋白质折叠为天然结构。在复性缓冲液中稀释溶解的蛋白质是胰岛素生产中最常用的复性方法，其他回收胰岛素原的方法包括蛋白质折叠液相色谱法（Protein-Folding Liquid Chromatography，PFLC）和透析。PFLC具有连续复性、生产率高和缓冲液消耗低等优势，但设备成本较高。透析法耗时较长，且在大规模生产中应用存在一定局限性。为了提高胰岛素原复性得率，可以在复性缓冲液中添加离液剂，同时缓冲液成分、氧化还原试剂、蛋白质浓度、温度、时间及融合标签等都会影响复性效率。表2 通过稀释法进行胰岛素原（PI）重折叠的优化条件六、酶促切割及制剂在生产“胰岛素原”途径中，需通过酶促切割去除重组人胰岛素/类似物前体分子中的C肽，以形成具有活性的胰岛素异二聚体。常使用胰蛋白酶和羧肽酶B（Carboxypeptidase B，CPB）进行切割，胰蛋白酶是丝氨酸内肽酶，能切割内部精氨酸和赖氨酸残基的羧基末端；CPB作为外肽酶可去除胰蛋白酶作用后C末端的精氨酸、赖氨酸和组氨酸等碱性氨基酸。可通过RP-HPLC监测酶促反应确定反应终点。反应终止方法多样，如将反应混合物pH调至2.5-3.5适合直接上阳离子交换色谱；添加蛋白酶抑制剂如抑肽酶，适用于后续为阴离子交换色谱/混合模式色谱的情况。在完成最终的色谱纯化后，胰岛素分子面临脱酰胺和聚集/纤维化的风险。为防止这些情况发生，需通过结晶和冻干去除残留的盐和缓冲液。胰岛素在锌离子存在下可形成晶体，通过离心、倾析或过滤分离胰岛素晶体，并洗涤去除残留锌。锌结晶后进行冷冻干燥，使胰岛素在储存时保持稳定，在使用前再将其溶解。为了抑制细菌生长、防止蛋白质聚集或改变胰岛素的体内吸收动力学，会向制剂中添加特定添加剂。间甲酚可抑制胰岛素淀粉样蛋白形成；胰岛素与锌和/或鱼精蛋白络合，能够制备中效或长效制剂，满足不同的临床需求。结语本文全面介绍了大肠杆菌包涵体生产重组人胰岛素的下游加工全过程，该过程步骤繁多，各环节紧密相连且相互影响，并提供了关键生产阶段实例，讨论了多模式纯化方案整合的实际问题，旨在为生产更高效、经济的胰岛素提供指导，以应对全球糖尿病患者对胰岛素的庞大需求。未来需优化整合各步骤，开发更高效、经济的生产工艺，以满足全球对胰岛素的需求，降低患者治疗成本。参考文献 [1] Singhvi P, Saneja A, Srichandan S, et al. Bacterial Inclusion Bodies: A Treasure Trove of Bioactive Proteins. Trends Biotechnol. 2020 May; 38(5):474-486. [2] Govender K, Naicker T, Baijnath S, et al. Sub/supercritical fluid chromatography employing water-rich modifier enables the purification of biosynthesized human insulin. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 15;1155:122126. [3] Zieliński M, Romanik-Chruścielewska A, Mikiewicz D, et al. Expression and purification of recombinant human insulin from E. coli 20 strain. Protein Expr Purif. 2019 May;157:63-69. 识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

微生物疗法

2024-10-21

·kbio.com

KBio Announces Supply Agreement for Plant-Derived Recombinant Aprotinin

Merck to use KBio’s plant-derived recombinant aprotinin for three years LONDON, October 21, 2024 – KBio, one of the leading developers of new biological treatments derived from a plant-based production system, and Merck, a leading science and technology company, today announced a three-year supply agreement with KBio to produce recombinant aprotinin, which is produced in Nicotiana benthamiana using the Company’s proprietary plant-based platform. Merck will be using aprotinin for expanding the animal free offerings of inhibitor products to their research customers. Aprotinin, or bovine pancreatic trypsin inhibitor, is a potent serine protease inhibitor that requires intricate folding to form an active and highly stable conformation. Aprotinin’s protease inhibitory activities are highly attractive and broadly used in a wide variety of in vitro applications. For example, aprotinin is widely used to improve recombinant protein recovery during cell fermentation, preserve protein and peptide integrity in complex biological samples such as blood, stabilize biological sutures and three-dimensional scaffold structures for tissue growth, and enhance stem cell growth in vitro while maintaining pluripotent potential. The availability of animal-free, high-activity and consistently sourced aprotinin will serve these existing markets while promoting more innovative use of this protease inhibitor in a variety of in vitro and cell-culture applications. “We’re delighted to enter this agreement and supply Merck with aprotinin, developed utilizing our novel plant-based platform,” said Barry Bratcher, cofounder and acting chief executive officer at KBio. “Our engineering process allows us to produce high-quality proteins in an unprecedented 8-10 weeks using our vertical grow towers. Our cost-effective approach requires lower space, water, and energy consumption. We look forward to supporting Merck on their important work.” There is an increased demand for animal free products and this partnership with KBio is part of Merck’s strategy to move away from animal sources. KBio aims to create a new generation of biologics using its plant-based platform, which has demonstrated the ability to create drug candidates at a fraction of the time and cost of conventional platforms. The Company is focused on discovering and developing monoclonal antibodies targeting validated pathways for immunological diseases and due to the speed and accuracy of its antibody production system, is positioned well to develop fast follower therapies against validated drug targets. KBio’s plant-based platform also has unique capabilities for addressing public health challenges where rapid development and large-scale production of vaccines and other bioactives are critical. Through a third-party partner, the Company is working with several health organizations that are funding its public health-specific pipeline. Formed in December 2021, KBio is a subsidiary of BAT with operations in the UK and U.S. For more information, please visit www.kbio.com. KBio Media Contact Andrew W. Mielach LifeSci Communications amielach@lifescicomms.com KBio Inc is a wholly owned subsidiary of KBio Holdings Limited, a BAT Group company.

100 项与抑酶肽(Bayer AG) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02971	抑酶肽(Bayer AG)	B02AB01	DB06692

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
出血	美国	Bayer HealthCare Pharmaceuticals, Inc.	1993-12-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膀胱癌	临床3期	美国	Bayer AG	2005-12-01
膀胱癌	临床3期	比利时	Bayer AG	2005-12-01
膀胱癌	临床3期	法国	Bayer AG	2005-12-01
膀胱癌	临床3期	德国	Bayer AG	2005-12-01
膀胱癌	临床3期	荷兰	Bayer AG	2005-12-01
膀胱癌	临床3期	瑞典	Bayer AG	2005-12-01
膀胱癌	临床3期	英国	Bayer AG	2005-12-01
食管癌	临床3期	美国	Bayer AG	2005-12-01
食管癌	临床3期	澳大利亚	Bayer AG	2005-12-01
食管癌	临床3期	奥地利	Bayer AG	2005-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2010	N/A	急性肾损伤	-	Aprotinin	蓋觸築鬱夢壓選觸願製(願顧顧衊窪鬱糧鬱廠夢) = 夢艱餘願齋鏇夢積壓積構壓淵簾獵鹽製構艱壓 (構醖顧廠蓋餘選夢襯顧, 11.5)	不佳	2010-11-16
				Amicar (Epsilon-aminocaproic acid)	蓋觸築鬱夢壓選觸願製(願顧顧衊窪鬱糧鬱廠夢) = 蓋觸觸窪醖憲鏇鹹觸繭構壓淵簾獵鹽製構艱壓 (構醖顧廠蓋餘選夢襯顧, 6.0)
ARVO2009	N/A	葡萄膜炎	-	Aprotinin	簾製選蓋鏇顧遞鑰夢積(簾鹹糧蓋遞膚壓構鏇壓) = 顧觸繭繭蓋窪積鑰淵範廠顧膚選顧簾鬱選積淵 (選糧願顧夢壓製鬱蓋餘 ) 更多	-	2009-04-01
Pubmed \| Eur J Cardiothorac Surg	N/A	-	112	Aprotinin	鏇遞壓醖製淵鑰鑰顧窪(積鬱鬱衊選觸壓簾醖齋) = 範遞積範醖鬱糧積築選窪壓願廠糧膚糧鹹艱獵 (鬱憲膚憲顧壓獵網齋獵 )	-	2006-02-01
				Aprotinin	鏇遞壓醖製淵鑰鑰顧窪(積鬱鬱衊選觸壓簾醖齋) = 廠簾鏇製觸選膚蓋鬱衊窪壓願廠糧膚糧鹹艱獵 (鬱憲膚憲顧壓獵網齋獵 )
Pubmed \| Can J Anaesth	N/A	术后认知功能障碍	-	Aprotinin	獵簾餘鏇繭齋範鑰艱顧(鏇齋齋觸願齋製壓構願) = 顧獵艱襯鬱構鬱淵積願觸壓願獵鬱餘襯憲鑰蓋 (構繭築廠簾憲蓋獵網選 )	-	2004-12-01
				Placebo	獵簾餘鏇繭齋範鑰艱顧(鏇齋齋觸願齋製壓構願) = 餘築齋憲鏇壓簾襯願窪觸壓願獵鬱餘襯憲鑰蓋 (構繭築廠簾憲蓋獵網選 )
ARVO2004	N/A	uPA \| tPA	-	Aprotinin treatment	齋觸醖膚衊鑰選憲積繭(艱積膚簾選蓋製餘糧憲) = plasminogen-dependent casein hydrolysis was restricted to the leading edge of migrating epithelial cells in no-aprotinin and aprotinin treated corneal tissue after PRK. The hydrolysis was inhibited by a polyclonal anti-uPA antibody, amiloride, but not with polyclonal anti-tPA antibody. No plasminogen-independent lysis was observed. 窪鏇積膚範蓋鑰餘鹽糧 (齋夢糧廠簾製蓋廠積蓋 ) 更多	-	2004-05-01
				No Aprotinin treatment